Increased risk of ARs w/ strong (eg, itraconazole, clarithromycin), moderate (eg, fluconazole, verapamil) & weak (eg, chlorzoxazone, ranitidine) CYP3A inhibitors. Reduced efficacy w/ strong (eg, rifampin, carbamazepine, St. John's wort) or moderate (eg, bosentan, efavirenz, etravine, modafinil) CYP3A inducers. Increased Cmax
& AUC by alcohol. Reduced efficacy of CYP2B6 substrates eg, bupropion, methadone.